Rs 21/Share Dividend In 2022-23: Small Cap Stock To Consider Dividend Again On Oct 9

Small cap pharmaceuticals sector company, Glenmark Life Sciences Ltd will consider and declare payment of interim dividend, if any on October 9, 2023 for the financial year 2023-24. Current market price of Glenmark Life Sciences share is Rs 617.85 per share with intraday gain of 0.13%. Glenmark Life Sciences shares gained 52% in last 6-months and soared 62% in last 1-year. Check details below:

Glenmark Life Sciences To Mull Dividend On Oct 9: According to the BSE filing of Glenmark Life Sciences dated September 5, 2023, "We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Monday, October 9, 2023, inter alia, to consider and declare payment of interim dividend, if any, on Equity Shares for the financial year 2023-24. It is further informed that the record date for payment of interim dividend, if declared, will be Tuesday, October 17, 2023."

Glenmark Life Sciences Dividend History: The company declared 3 dividends since November 22, 2021. It offers a dividend yield of 3.38% if current market price of the stock is taken into consideration. In the past 12 months, Glenmark Life Sciences Ltd announced an equity dividend amounting to Rs 21.00 per share, according to Trendlyne.

Glenmark Life Sciences Stock Outlook & Return: Current market price of Glenmark Life Sciences stock on BSE is Rs 617.85 per share. Its 52-week high price is Rs 674.00 per share and 52-week low price is Rs 369.00 per share, respectively. The company has a market capitalisation of Rs 7586.27 crore. Glenmark Life Sciences shares rallied 48% YTD and fell 7% in last 2-years. In last 3-months, Glenmark Life Sciences stock surged 7%.

Glenmark Life Sciences Financials: The company for the quarter ended June 30, 2023 announced its total revenue at Rs 5784.5 million, up 18% YoY. Glenmark Life's net profit during the period declared at Rs 1354.5 million, up 24% on year. The active pharmaceutical ingredients (API) manufacturing arm of Glenmark Pharmaceuticals (GPL) witnessed a 14.1% YoY surge in cost of raw materials to Rs 2,982.13 million in the ongoing fiscal year. It announced EBITDA (earnings before interest, taxes, depreciation, and amortization) at Rs 1,950 million, up 24.8% YoY.

Disclaimer: The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.